Immune Pharmaceuticals, Inc. (FZRQ.F)

0,0060 +0,0035 (+140,00%) Börsenschluss: 10:08AM CEST

Immune Pharmaceuticals, Inc.

1 Bridge Plaza North
Suite 270
Fort Lee, NJ 07024
United States
201-464-2677
https://www.immunepharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 7

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John P. Clark	Controller & Principal Accounting Officer	175k	N/A	1971
Mr. Gary H. Rabin	Interim CEO & Director	N/A	N/A	1965
Mr. Christine J. Petraglia	Director of Investor Relations	N/A	N/A	N/A
Dr. Miri Ben-Ami	Pres of Immune Oncology Pharmaceuticals Inc	N/A	N/A	N/A
Dr. Boris Shor	Exec. Director of R&D & Scientific Partnerships	N/A	N/A	N/A
Mr. Ranch C. Kimball	Strategic Advisor	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2018 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.

Corporate Governance

Immune Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.